Ubs Oncology Impact Fund L.P.
10% Owner at Werewolf Therapeutics, Inc. (HOWL)
Purchase track record
Not enough history. Based on 0 purchases with a full 90 days of price history.
—
Avg. 90-day return—
vs. S&P 500—
Beat the market—
Paper profit on buys$0
Total bought / sold$0 / $825K
Reported trades
| Filed | Stock | Type | Shares | Price | Value | Since |
|---|---|---|---|---|---|---|
| Dec 1SEC | HOWLWerewolf Therapeutics, Inc. | Sell Plan | 60,7335,065,037 held (−1%) | $0.98 | $60K | +0.0% |
| Dec 1SEC | HOWLWerewolf Therapeutics, Inc. | Sell Plan | 20,2775,044,760 held (−0%) | $0.99 | $20K | -1.0% |
| Dec 1SEC | HOWLWerewolf Therapeutics, Inc. | Sell Plan | 60,9174,983,843 held (−1%) | $0.94 | $57K | +4.3% |
| Nov 12SEC | HOWLWerewolf Therapeutics, Inc. | Sell Plan | 68,4805,836,240 held (−1%) | $1.11 | $76K | -11.7% |
| Nov 12SEC | HOWLWerewolf Therapeutics, Inc. | Sell Plan | 48,5705,787,670 held (−1%) | $1.18 | $57K | -16.9% |
| Nov 12SEC | HOWLWerewolf Therapeutics, Inc. | Sell Plan | 55,8105,731,860 held (−1%) | $1.14 | $64K | -14.0% |
| Nov 12SEC | HOWLWerewolf Therapeutics, Inc. | Sell Plan | 40,6695,691,191 held (−1%) | $1.09 | $44K | -10.1% |
| Oct 29SEC | HOWLWerewolf Therapeutics, Inc. | Sell Plan | 72,7096,645,961 held (−1%) | $1.72 | $125K | -43.0% |
| Oct 29SEC | HOWLWerewolf Therapeutics, Inc. | Sell Plan | 69,0686,576,893 held (−1%) | $1.64 | $113K | -40.2% |
| Oct 29SEC | HOWLWerewolf Therapeutics, Inc. | Sell Plan | 134,2406,442,653 held (−2%) | $1.55 | $208K | -36.8% |
- Sell
10% Owner Ubs Oncology Impact Fund L.P. sold $60K of HOWL at $0.98 — pre-scheduled 10b5-1 plan sale.
- Sell
10% Owner Ubs Oncology Impact Fund L.P. sold $20K of HOWL at $0.99 — pre-scheduled 10b5-1 plan sale.
- Sell
10% Owner Ubs Oncology Impact Fund L.P. sold $57K of HOWL at $0.94 — pre-scheduled 10b5-1 plan sale.
- Sell
10% Owner Ubs Oncology Impact Fund L.P. sold $76K of HOWL at $1.11 — pre-scheduled 10b5-1 plan sale.
- Sell
10% Owner Ubs Oncology Impact Fund L.P. sold $57K of HOWL at $1.18 — pre-scheduled 10b5-1 plan sale.
- Sell
10% Owner Ubs Oncology Impact Fund L.P. sold $64K of HOWL at $1.14 — pre-scheduled 10b5-1 plan sale.